BUSINESS
Nichi-Iko Announces Launching of Authorized Generic of Allegra in June; Is Late Launch Part of Sanofi’s Carefully Worked-out Strategy?
The debut of Japan’s first authorized generic (AG) will come at an unexpected time. Nichi-Iko Pharmaceutical, which is allied with Sanofi K.K., has announced that it will launch a generic version of Sanofi’s anti-allergy drug Allegra (fexofenadine) in June. Nichi-Iko…
To read the full story
BUSINESS
- Enhertu Earns EMA Panel OK for HER2 Positive Solid Tumors
May 25, 2026
- Datroway Snares US Approval in 1st-Line TNBC: Daiichi Sankyo
May 25, 2026
- Net Profit at 24 Japan Drug Makers Tops 2 Trillion Yen, Led by Astellas and Sumitomo
May 25, 2026
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
- Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





